Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629960 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 265
- Enrollment target
NCT07629960 is a Phase 1 study that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 265 participants.
The verdict
NCT07629960, a Phase 1 study, is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 265 participants
- Enrollment target
Study Summary
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
Interventions
- DRUG BLU-924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2031-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07629960
The ClinicalTrials.gov registry entry for NCT07629960 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BLU-924 is the first listed.
NCT07629960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07629960 about?
NCT07629960 is a clinical study titled "A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations". A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
What is the current status of trial NCT07629960?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 265 participants. The study started on 2026-06-30. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07629960?
The interventions under investigation include: BLU-924 (DRUG).
Who is sponsoring clinical trial NCT07629960?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.